(SLQT) Selectquote - Ratings and Ratios
Medicare, Medicare, Life, Pharmacy, Insurance
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 78.4% |
| Value at Risk 5%th | 114% |
| Relative Tail Risk | -11.39% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.63 |
| Alpha | -76.19 |
| CAGR/Max DD | 0.35 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.434 |
| Beta | 1.209 |
| Beta Downside | 1.472 |
| Drawdowns 3y | |
|---|---|
| Max DD | 78.02% |
| Mean DD | 40.62% |
| Median DD | 42.97% |
Description: SLQT Selectquote October 25, 2025
SelectQuote, Inc. (NYSE: SLQT) runs a technology-driven, direct-to-consumer platform that sells a range of insurance and health-care services across three segments: Senior (Medicare Advantage, Medicare Supplement, Part D and related ancillary products), Healthcare Services (pharmacy and chronic-condition management solutions such as SelectRx, Healthcare Select, Home™ and SelectPatient Management), and Life (term life, final-expense and other ancillary policies). The firm also generates leads for non-commercial auto, homeowners, property and casualty lines.
Key operating metrics from the most recent fiscal year show revenue of roughly $1.1 billion, with the Senior segment contributing about 55 % of total sales and delivering a combined ratio near 92 %, indicating modest underwriting profitability. The business benefits from macro trends such as the aging U.S. population-projected to reach 21 % of residents by 2030-and the continued growth of Medicare enrollment, which drives demand for both core and ancillary senior products. Additionally, the shift toward digital acquisition channels has helped SelectQuote maintain a customer acquisition cost (CAC) that is roughly 20 % lower than the industry average for comparable insurers.
For a deeper quantitative assessment, you may find ValueRay’s analytics useful for modeling SLQT’s earnings sensitivity to Medicare enrollment trends and digital acquisition dynamics.
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income (61.7m TTM) > 0 and > 6% of Revenue (6% = 93.8m TTM) |
| FCFTA -0.02 (>2.0%) and ΔFCFTA -3.18pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 7.44% (prev 10.15%; Δ -2.71pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.01 (>3.0%) and CFO -16.7m <= Net Income 61.7m (YES >=105%, WARN >=100%) |
| Net Debt (412.1m) to EBITDA (133.2m) ratio: 3.09 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.54 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (185.8m) change vs 12m ago 9.03% (target <= -2.0% for YES) |
| Gross Margin 35.89% (prev 44.80%; Δ -8.90pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 132.8% (prev 120.4%; Δ 12.37pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.67 (EBITDA TTM 133.2m / Interest Expense TTM 68.2m) >= 6 (WARN >= 3) |
Altman Z'' 0.20
| (A) 0.10 = (Total Current Assets 332.0m - Total Current Liabilities 215.7m) / Total Assets 1.21b |
| (B) -0.21 = Retained Earnings (Balance) -252.6m / Total Assets 1.21b |
| (C) 0.10 = EBIT TTM 114.0m / Avg Total Assets 1.18b |
| (D) -0.38 = Book Value of Equity -250.9m / Total Liabilities 660.0m |
| Total Rating: 0.20 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 61.91
| 1. Piotroski 3.0pt |
| 2. FCF Yield -3.73% |
| 3. FCF Margin -1.56% |
| 4. Debt/Equity 0.77 |
| 5. Debt/Ebitda 3.09 |
| 6. ROIC - WACC (= 6.24)% |
| 7. RoE 12.29% |
| 8. Rev. Trend 69.31% |
| 9. EPS Trend 40.51% |
What is the price of SLQT shares?
Over the past week, the price has changed by -0.73%, over one month by -2.86%, over three months by -33.98% and over the past year by -58.91%.
Is SLQT a buy, sell or hold?
- Strong Buy: 2
- Buy: 0
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the SLQT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4.5 | 230.9% |
| Analysts Target Price | 4.5 | 230.9% |
| ValueRay Target Price | 1.1 | -19.9% |
SLQT Fundamental Data Overview December 19, 2025
P/E Trailing = 137.0
P/E Forward = 66.6667
P/S = 0.1542
P/B = 0.8076
Beta = 1.192
Revenue TTM = 1.56b USD
EBIT TTM = 114.0m USD
EBITDA TTM = 133.2m USD
Long Term Debt = 324.8m USD (from longTermDebt, last quarter)
Short Term Debt = 73.2m USD (from shortTermDebt, last quarter)
Debt = 422.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 412.1m USD (from netDebt column, last quarter)
Enterprise Value = 653.2m USD (241.1m + Debt 422.8m - CCE 10.7m)
Interest Coverage Ratio = 1.67 (Ebit TTM 114.0m / Interest Expense TTM 68.2m)
FCF Yield = -3.73% (FCF TTM -24.4m / Enterprise Value 653.2m)
FCF Margin = -1.56% (FCF TTM -24.4m / Revenue TTM 1.56b)
Net Margin = 3.95% (Net Income TTM 61.7m / Revenue TTM 1.56b)
Gross Margin = 35.89% ((Revenue TTM 1.56b - Cost of Revenue TTM 1.00b) / Revenue TTM)
Gross Margin QoQ = 20.36% (prev 30.12%)
Tobins Q-Ratio = 0.54 (Enterprise Value 653.2m / Total Assets 1.21b)
Interest Expense / Debt = 2.79% (Interest Expense 11.8m / Debt 422.8m)
Taxrate = 19.13% (-7.20m / -37.7m)
NOPAT = 92.2m (EBIT 114.0m * (1 - 19.13%))
Current Ratio = 1.54 (Total Current Assets 332.0m / Total Current Liabilities 215.7m)
Debt / Equity = 0.77 (Debt 422.8m / totalStockholderEquity, last quarter 546.9m)
Debt / EBITDA = 3.09 (Net Debt 412.1m / EBITDA 133.2m)
Debt / FCF = -16.90 (negative FCF - burning cash) (Net Debt 412.1m / FCF TTM -24.4m)
Total Stockholder Equity = 501.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.11% (Net Income 61.7m / Total Assets 1.21b)
RoE = 12.29% (Net Income TTM 61.7m / Total Stockholder Equity 501.6m)
RoCE = 13.80% (EBIT 114.0m / Capital Employed (Equity 501.6m + L.T.Debt 324.8m))
RoIC = 11.48% (NOPAT 92.2m / Invested Capital 803.5m)
WACC = 5.24% (E(241.1m)/V(663.9m) * Re(10.47%) + D(422.8m)/V(663.9m) * Rd(2.79%) * (1-Tc(0.19)))
Discount Rate = 10.47% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.63%
Fair Price DCF = unknown (Cash Flow -24.4m)
EPS Correlation: 40.51 | EPS CAGR: 155.1% | SUE: 0.04 | # QB: 0
Revenue Correlation: 69.31 | Revenue CAGR: 15.07% | SUE: 0.35 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.10 | Chg30d=-0.010 | Revisions Net=+1 | Analysts=1
EPS current Year (2026-06-30): EPS=0.11 | Chg30d=+0.010 | Revisions Net=-1 | Growth EPS=-55.3% | Growth Revenue=+10.8%
EPS next Year (2027-06-30): EPS=0.44 | Chg30d=+0.300 | Revisions Net=-1 | Growth EPS=+300.0% | Growth Revenue=+8.0%
Additional Sources for SLQT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle